Keywords
Hepatitis C ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

137 Search results.

RO5024048 in Combination with Pegasys and Copegus in Chronic Hep C NCT01057667 - Eligibility Criteria

- 4/15/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4; ODM derived from: https://clinicaltrials.gov/show/NCT01057667

Eligibility Hepatitis C Virus NCT02105454

- 4/11/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048); ODM derived from: https://clinicaltrials.gov/show/NCT02105454

Eligibility Hepatitis C Virus NCT02023112

- 4/10/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection; ODM derived from: https://clinicaltrials.gov/show/NCT02023112

Eligibility Hepatitis C Virus Infection NCT02461563

- 4/10/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004); ODM derived from: https://clinicaltrials.gov/show/NCT02461563

Eligibility Hepatitis C NCT02496078

- 4/10/19 - 1 form, 3 itemgroups, 15 items, 1 language
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection; ODM derived from: https://clinicaltrials.gov/show/NCT02496078

Eligibility Hepatitis C NCT02455167

- 4/10/19 - 1 form, 2 itemgroups, 24 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis; ODM derived from: https://clinicaltrials.gov/show/NCT02455167

Eligibility Hepatitis C NCT02392494

- 4/10/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002); ODM derived from: https://clinicaltrials.gov/show/NCT02392494

Eligibility Hepatitis C NCT02214420

- 4/10/19 - 1 form, 2 itemgroups, 24 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
SMV + SOF With/Without RBV for IFN-II Patients With CHC; ODM derived from: https://clinicaltrials.gov/show/NCT02214420

Eligibility Hepatitis C NCT02204475

- 4/9/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066); ODM derived from: https://clinicaltrials.gov/show/NCT02204475

Eligibility Hepatitis C NCT02203149

- 4/9/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058); ODM derived from: https://clinicaltrials.gov/show/NCT02203149

Eligibility Hepatitis C NCT02068963

- 4/9/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing; ODM derived from: https://clinicaltrials.gov/show/NCT02068963

Eligibility Hepatitis C NCT02053519

- 4/9/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Can Vitamin D Supplementation Improve Hepatitis C Cure Rates; ODM derived from: https://clinicaltrials.gov/show/NCT02053519